Entera Bio Ltd. SEC filings ENTX
Entera Bio Ltd. has 418 filings in SEC EDGAR's recent list, going back to May 1, 2015. Its latest annual report, Form ARS, was filed on Jun 3, 2026 for the period ended Jun 3, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 27, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 28, 2026 | — |
| D | Filing | Aug 12, 2026 | — |
| EFFECT | Filing | May 15, 2026 | — |
| CORRESP | Letter to the SEC | May 13, 2026 | — |
| UPLOAD | Letter from the SEC | May 12, 2026 | — |
| EFFECT | Filing | Jun 6, 2025 | — |
| CORRESP | Letter to the SEC | Jun 4, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2025 | — |
| UPLOAD | Letter from the SEC | May 23, 2025 | — |
| CORRESP | Letter to the SEC | May 20, 2025 | — |
| UPLOAD | Letter from the SEC | May 6, 2025 | — |
| EFFECT | Filing | Feb 14, 2024 | — |
| CORRESP | Letter to the SEC | Feb 14, 2024 | — |
| D | Filing | Jan 2, 2024 | — |
| PRER14A | Filing | Jul 28, 2023 | — |
| 25-NSE/A | Filing | Jun 29, 2023 | — |
| EFFECT | Filing | Jun 9, 2022 | — |
| EFFECT | Filing | Jun 9, 2022 | — |
| CORRESP | Letter to the SEC | Jun 7, 2022 | — |
| CORRESP | Letter to the SEC | Jun 7, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2022 | — |
| EFFECT | Filing | Jul 22, 2020 | — |
| CORRESP | Letter to the SEC | Jul 20, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 17, 2020 | — |
| EFFECT | Filing | Jun 24, 2020 | — |
| CORRESP | Letter to the SEC | Jun 22, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2020 | — |
| D | Filing | Dec 26, 2019 | — |
| EFFECT | Filing | Jun 27, 2018 | — |
| CORRESP | Letter to the SEC | Jun 26, 2018 | — |
| CERT | Filing | Jun 26, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 26, 2018 | — |
| CORRESP | Letter to the SEC | Jun 25, 2018 | — |
| CORRESP | Letter to the SEC | Jun 25, 2018 | — |
| 8-A12B | Form 8-a12b | Jun 25, 2018 | — |
| CORRESP | Letter to the SEC | Jun 25, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 22, 2018 | — |
| CORRESP | Letter to the SEC | Jun 15, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2018 | — |
| CORRESP | Letter to the SEC | Jan 29, 2018 | — |
| CORRESP | Letter to the SEC | Jan 29, 2018 | — |
| CORRESP | Letter to the SEC | Jan 19, 2018 | — |
| CORRESP | Letter to the SEC | Jan 19, 2018 | — |
| CORRESP | Letter to the SEC | Nov 20, 2017 | — |
| CORRESP | Letter to the SEC | Nov 17, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 17, 2017 | — |
| DRSLTR | Filing | Nov 3, 2017 | — |
| DRS/A | Filing | Nov 3, 2017 | — |
| D | Filing | Oct 19, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2017 | — |
| DRSLTR | Filing | Sep 20, 2017 | — |
| DRS/A | Filing | Sep 20, 2017 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2017 | — |
| DRS | Filing | Jul 14, 2017 | — |
| DRSLTR | Filing | May 18, 2015 | — |
| UPLOAD | Letter from the SEC | May 1, 2015 | — |
Showing 57 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ENTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Jerusalem
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1638097
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.